Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Bardelli

Showing results (221-230 of 259) with videos related to

Pageof 26
Sort By:
Cancer Discovery|May 6, 2022
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer PatientsGiovanni Crisafulli, Andrea Sartore-Bianchi, Luca Lazzari, et al.
Clinical Colorectal Cancer|September 13, 2020
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal CancerFederica Tosi, Andrea Sartore-Bianchi, Sara Lonardi, et al.
Science Translational Medicine|May 21, 2025
Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancerElena Grassi, Valentina Vurchio, George D Cresswell, et al.
Journal of the National Cancer Institute|April 7, 2021
EGFR Amplification in Metastatic Colorectal CancerGiovanni Randon, Rona Yaeger, Jaclyn F Hechtman, et al.
Cancer Discovery|April 21, 2026
Pharmacological inhibition of PMS2 induces MMR deficiency and response to immune checkpoint blockadeJulian Blagg, Philippe Riou, Alexia Hervieu, et al.
Gut|October 7, 2017
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancerLudovic Barault, Alessio Amatu, Giulia Siravegna, et al.
Nature Medicine|August 7, 2015
Toward understanding and exploiting tumor heterogeneityAsh A Alizadeh, Victoria Aranda, Alberto Bardelli, et al.
Cancer Discovery|June 5, 2013
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerAlberto Bardelli, Simona Corso, Andrea Bertotti, et al.
BJC Reports|March 27, 2025
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancersPeter Gallagher, Christian Rolfo, Elena Elez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 BlockadeGiuseppe Lo Russo, Massimo Moro, Michele Sommariva, et al.
Pageof 26

Showing results (221-230 of 259) with videos related to

Sort By:
Pageof 26
Cancer Discovery|May 6, 2022
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer PatientsGiovanni Crisafulli, Andrea Sartore-Bianchi, Luca Lazzari, et al.
Clinical Colorectal Cancer|September 13, 2020
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal CancerFederica Tosi, Andrea Sartore-Bianchi, Sara Lonardi, et al.
Science Translational Medicine|May 21, 2025
Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancerElena Grassi, Valentina Vurchio, George D Cresswell, et al.
Journal of the National Cancer Institute|April 7, 2021
EGFR Amplification in Metastatic Colorectal CancerGiovanni Randon, Rona Yaeger, Jaclyn F Hechtman, et al.
Cancer Discovery|April 21, 2026
Pharmacological inhibition of PMS2 induces MMR deficiency and response to immune checkpoint blockadeJulian Blagg, Philippe Riou, Alexia Hervieu, et al.
Gut|October 7, 2017
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancerLudovic Barault, Alessio Amatu, Giulia Siravegna, et al.
Nature Medicine|August 7, 2015
Toward understanding and exploiting tumor heterogeneityAsh A Alizadeh, Victoria Aranda, Alberto Bardelli, et al.
Cancer Discovery|June 5, 2013
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerAlberto Bardelli, Simona Corso, Andrea Bertotti, et al.
BJC Reports|March 27, 2025
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancersPeter Gallagher, Christian Rolfo, Elena Elez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 BlockadeGiuseppe Lo Russo, Massimo Moro, Michele Sommariva, et al.
Pageof 26